Hillhurst Biopharma

11:00 AM - 11:15 AM (PDT), Wednesday, June 15, 2022
Therapeutic medical gases have the potential to address a wide spectrum of diseases, but have been limited by inhaled delivery, which for conscious patients is inaccurate in dosing, potentially unsafe, and highly intrusive.

Hillhurst solves the delivery challenge of medical gases using its proprietary GLASS™ (Gas in Liquid Advanced Stability System) technology platform to infuse those medical gases into liquids as beverage drug products for patient use. Our lead oral liquid drug delivers low doses of the FDA-designated medical gas CO for Sickle Cell Disease and Parkinson’s Disease. An IND with the FDA is in place, and a Phase 1 clinical study is scheduled for Q2 2022. Our pipeline includes a drinkable drug product that delivers the FDA approved medical gas nitrous oxide for Pain.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
HBI-002 for sickle cell disease
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
President and CEO
Hillhurst Biopharmaceuticals, Inc.